Ankylosing spondylitis
MDedge Crosswords
Ankylosing Spondylitis Treatment
Conference Coverage
Tofacitinib effective for ankylosing spondylitis in phase 3
The oral JAK inhibitor was significantly more effective than placebo at primary and secondary endpoints. Safety risks were comparable to those for...
Conference Coverage
COVID-19 risks in rheumatic disease remain unclear
Elevated COVID-19-related risks, many associated with comorbidities, emerged in a match-control study, whereas a systematic review delivers more...
MDedge Crosswords
Ankylosing Spondylitis: Differential Diagnosis
Feature
Novel study explores link between primary immunodeficiencies, rheumatic diseases
Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with...
From the Journals
Lower TNF inhibitor efficacy observed in women with nonradiographic axSpA
Findings are similar to those reported for sex differences in TNF inhibitor response seen in radiographic disease.
News from the FDA/CDC
FDA issues new NSAIDs warning for second half of pregnancy
The FDA action expands on earlier warnings about agents in this drug class, which the FDA previously cautioned about taking after week 30 of...
MDedge Crosswords
Evaluating Ankylosing Spondylitis
From the Journals
Shingrix effective in older adults with preexisting immune-mediated disorders
The most common immune-mediated disorders in two phase 3 clinical trials of the vaccine were psoriasis, spondyloarthropathy, rheumatoid arthritis...
Conference Coverage
Strategic approach mitigates impact of antidrug antibodies in patients with rheumatic diseases
Consider dose escalation and adding an immunomodulator to overcome the impact of antidrug antibodies in rheumatic disease patients.
Conference Coverage
Dr. Len Calabrese gives advice on vaccinating adult patients with rheumatic disease
He highlights safety protocols and advises on recommended vaccines in rheumatology practice.